RECURRENT ACUTE MYELOID LEUKEMIA

This study tests a combination of two or three drugs (ivosidenib, venetoclax, with or without azacitidine) in people with certain blood cancers that have an IDH1 mutation. The goal is to find the best dose and see how well the drugs control the cancer. About 96 adults with acute …

This study tests a combination of three drugs (ASTX727, venetoclax, and gilteritinib) for people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a specific gene change called FLT3. The goal is to find the best dose and see how well the drugs work togeth…

This study tests a new approach for adults with blood cancers like AML that have come back or not responded to treatment. Participants receive intense chemotherapy followed immediately by a donor stem cell transplant, plus drugs to prevent graft-versus-host disease. The goal is t…

This study tests adding the drug venetoclax to standard chemotherapy for people with acute myeloid leukemia (AML), either newly diagnosed or that has returned or not responded to treatment. About 116 adults will take part to find the best dose and see how well the combination wor…

This early-phase study tests whether an oral drug called ASTX727 (which combines cedazuridine and decitabine) plus a shot called filgrastim can safely help prevent leukemia from coming back in children who have already had a stem cell transplant for high-risk acute myeloid leukem…

This study tests a combination of two drugs—CPX-351 (a liposomal form of standard chemotherapy) and quizartinib—in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo can control the cancer. …

This study is for people with acute myeloid leukemia (AML) that has come back or not improved with standard treatments. It tests a combination of three or four oral drugs designed to block cancer growth from different angles. The goal is to see if this mix is safe and can help co…

This early-phase trial tests a combination of three drugs—pembrolizumab, decitabine, and venetoclax—in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the dr…

This study is for people with certain blood cancers (acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome) that have a specific genetic change called a FLT3 mutation. The cancer has either come back or not responded to prior treatment. Th…

This early-phase study tests two different drug combinations for people whose acute myeloid leukemia has returned or not responded to prior treatment. The goal is to find safer and more effective ways to control the disease. About 24 adults will participate, receiving either taze…

This early-stage study is testing a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with blood cancers MDS and AML. The goal is to find the safest dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment …

This early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The cancer must have a FLT3 mutation plus either a…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …

This study tests a combination of two drugs (enasidenib and azacitidine) in about 50 people with a specific genetic mutation (IDH2) and acute myeloid leukemia that has returned or not responded to prior therapy. The goal is to see if the combination can stop cancer cell growth an…

This study tests a new treatment for adults with aggressive blood cancers like acute myeloid leukemia (AML) that are hard to cure. Patients receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and total body radiation, followed by a stem cell transplant from a h…

This study tests whether combining three drugs—quizartinib, decitabine, and venetoclax—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The trial includes 73 adults aged 60 or older who cannot have standard intensive chemotherapy, or whose ca…

This study tests a combination of two drugs, CPX-351 and venetoclax, in adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The goal is to see if this combo can help more patients achieve remission. About 52 participants will receiv…

This study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia or high-risk myelodysplastic syndrome that is either newly diagnosed or has returned/not responded to treatment. The goal is to see if this mix…

This early-stage trial tests a new drug called miRisten in 12 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers hope miRisten can block cancer cell growth…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This study tests whether combining two drugs—CPX-351 (a chemotherapy) and ivosidenib (a targeted therapy)—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have an IDH1 gene mutation. About 30 adults who are either newly diagnosed or…

This study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 pa…

This early-stage study is testing a new treatment called LILRA6 CAR-T for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …

This early-phase trial tests a new treatment using specially engineered immune cells (CD83 CAR T cells) for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The cells are designed to find and destroy leukemia cells while reducing th…

This early-phase study tests whether adding ruxolitinib to two standard drugs (azacitidine and venetoclax) is safe and tolerable for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 51 adults will receive the combination to fin…

This study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…

This study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or a fast-growing form of chronic myeloid leukemia. The goal is to see how well these drugs ki…

This early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…